EPISODE · Jun 18, 2025 · 29 MIN
Trevi Therapeutics CEO Jennifer Good Discusses Oral Haduvio Benefit in Chronic Cough
from WTR Healthcare Happenings · host Joe Brunetto
Trevi Therapeutics CEO Jennifer Good joins us on this week’s WTR Biotech Spotlight to talk about the recent and impressive clinical data for Haduvio in IPF-associated chronic cough and refractory chronic cough. We discuss Haduvio’s unique mechanism and unscheduled status, supported by a human abuse study. Listen to learn more about Trevi Therapeutics and how Haduvio could change the chronic cough treatment landscape.
What this episode covers
Trevi Therapeutics CEO Jennifer Good joins us on this week’s WTR Biotech Spotlight to talk about the recent and impressive clinical data for Haduvio in IPF-associated chronic cough and refractory chronic cough. We discuss Haduvio’s unique mechanism and unscheduled status, supported by a human abuse study. Listen to learn more about Trevi Therapeutics and how Haduvio could change the chronic cough treatment landscape.
NOW PLAYING
Trevi Therapeutics CEO Jennifer Good Discusses Oral Haduvio Benefit in Chronic Cough
No transcript for this episode yet
Similar Episodes
No similar episodes found.